Fig. 4From: Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational studyPFS curves of Ribociclib + AI and Ribociclib + Fulvestrant with or without PPIs. (Kaplan meier estimates) AI: aromatase inhibitor, PFS: progression free survival, PPI: proton pomp inhibitörBack to article page